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Abstract
Sialic acids are monosaccharides that normally terminate the glycan chains of cell surface
glyco-proteins and -lipids in mammals, and are highly enriched in the central nervous tis-
sue. Sialic acids are conjugated to proteins and lipids (termed “sialylation”) by specific
sialyltransferases, and are removed (“desialylation”) by neuraminidases. Cell surface sialic
acids are sensed by complement factor H (FH) to inhibit complement activation or by
sialic acid-binding immunoglobulin-like lectin (SIGLEC) receptors to inhibit microglial acti-
vation, phagocytosis, and oxidative burst. In contrast, desialylation of cells enables bind-
ing of the opsonins C1, calreticulin, galectin-3, and collectins, stimulating phagocytosis of
such cells. Hypersialylation is used by bacteria and cancers as camouflage to escape
immune recognition, while polysialylation of neurons protects synapses and neuro-
genesis. Insufficient lysosomal cleavage of sialylated molecules can lead to lysosomal
accumulation of lipids and aggregated proteins, which if excessive may be expelled into
the extracellular space. On the other hand, desialylation of immune receptors can acti-
vate them or trigger removal of proteins. Loss of inhibitory SIGLECs or FH triggers
reduced clearance of aggregates, oxidative brain damage and complement-mediated reti-
nal damage. Thus, cell surface sialylation recognized by FH, SIGLEC, and other immune-
related receptors acts as a major checkpoint inhibitor of innate immune responses in the
central nervous system, while excessive cleavage of sialic acid residues and consequently
removing this checkpoint inhibitor may trigger lipid accumulation, protein aggregation,
inflammation, and neurodegeneration.
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1 | THE INNATE IMMUNE RESPONSE OF
THE BRAIN
The blood brain barrier normally restricts access of antibodies and
white blood cells into the central nervous system (CNS, i.e., brain, spi-
nal cord, and retina). Thus, under homeostatic conditions, the adaptive
immune response of the CNS is very limited, and the innate immune
response depends on endogenous brain cells, in particular the
microglia. Microglia are the main phagocytes of the CNS. In the
healthy brain, the innate immune response of microglia is turned
“OFF,” a state that has been termed “resting” or “homeostatic.” How-
ever, even in this state, microglial processes are highly active and
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continuously surveying the CNS for danger in the form of pathogens or
damage (Nimmerjahn, Kirchhoff, & Helmchen, 2005). Upon encounter of
danger signals, the innate immune response is turned “ON,” and the
microglia switch into various “activated” phenotypes. Activated microglia
may: (a) retract their processes and the whole cell becomes motile,
(b) release reactive oxygen and nitrogen species to kill pathogens,
(c) release chemokines and cytokines attracting and activating other
immune cells (e.g., monocytes and T lymphocytes), and (d) become highly
phagocytic, to remove pathogens, dead or dying neurons and clear up
debris. However, excessive phagocytosis or inflammation may contribute
to the pathogenesis of stroke, brain trauma, epilepsy, brain infections,
schizophrenia, and neurodegenerative disease (such as Alzheimer's dis-
ease [AD]), emphasizing the importance of understanding microglial acti-
vation (Vilalta & Brown, 2018).
Microglial activation, and thus the innate immune response, is
turned “ON” by stimulation of pattern recognition receptors (such as
the toll-like receptors) or other cell surface receptors sensing the pres-
ence of pathogens or damage. On the other side, microglial activation,
and the innate immune response generally, can cause collateral dam-
age to nonregenerative neurons, and thus, has strong “OFF” switches
that act as innate immune checkpoints. Sialic acid residues on the sur-
face of brain cells are molecules signaling the presence of “intact self”
and act as such an “OFF” switch and checkpoint suppressing innate
immunity. Consequently, sialic acid residues can prevent microglial
attack of intact self. Here, we review the current literature on how
these sialic acid residues suppress and regulate the innate immune
system of the CNS, in particular microglia, and what happens when
this regulatory switch of the immune response is removed.
2 | SIALIC ACIDS
Sialic acid (Sia) is a generic term for a family of nine carbon monosaccha-
rides, that are derivatives of neuraminic acid. Sia is the typical residue termi-
nating the sugar chains of glycolipids and glycoproteins expressed on the
cell surface of vertebrates (T. Angata & Varki, 2002; Varki, 2017). There are
three main types of Sias in vertebrates, namely N-acetylneuraminic acid
(Neu5Ac),N-glycolylneuraminic acid (Neu5Gc), and deaminoneuraminic acid
(Kdn). Most mammals produce Neu5Ac and Neu5Gc, while humans have
lost the capacity to produce Neu5Gc (Varki, 2017). Sias can be modified by
several postsynthesis modifications, such as methylation, sulfation,
lactylation, acetylation, and lactonization and can be added to sugar chains,
a process named “sialylation,” to form sialoglycoproteins and
sialoglycolipids. Thus, the Sia family consists of more than 50 members with
different structures (T. Angata & Varki, 2002).
The biosynthesis of Sia takes place in the cytosol and involves four
steps and three enzymes (Figure 1). Two rate-limiting steps are carried
out by the bifunctional glucosamine (UDP-N-acetyl)-2-epimerase/N-
acetylmannosamine kinase (GNE; Keppler, 1999). GNE catalyses the con-
version from uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) to
N-acetyl-D-mannosamine (ManNAc), and phosphorylates ManNAc to
form N-acetyl-mannosamine 6-phosphate (ManNAc-6-P). ManNAc-6-P is
then condensed and dephosphorylated in two steps to generate Neu5Ac.
In the nucleus, Neu5Ac is conjugated by the cytidine monophosphate N-
acetylneuraminic acid synthetase (CMAS; Munster-Kuhnel et al., 2004)
with cytidine 5-monophosphate (CMP) to form the active CMP-Neu5Ac.
After transport of CMP-Neu5Ac from the nucleus to the Golgi apparatus,
sialyltransferases conjugate Neu5Ac to a galactose (Gal), an N-
acetylgalactosamine (GalNAc), or another Sia residue of various proteins
or lipids (Figure 1; Chen & Varki, 2010). Humans have approximately
20 different sialyltransferases that add Sia to different acceptor sugars
(Gal, GalNAc, Sia) by using distinct linkages (α2,3-, α2,6-, α2,8-) between
the Sia residues and the underlying acceptor sugar. Moreover, Sias can
form homopolymers with different degrees of polymerization via inter-
sialyl linkages. For instance, polysialic acid (polySia) is a homopolymer of
α2,8-linked Neu5Ac monomers with a degree of polymerization between
10 and around 200, and is highly expressed in the developing CNS
(Schnaar, Gerardy-Schahn, & Hildebrandt, 2014).
Sias are detected on most cell surfaces and secreted molecules
(Figure 2). Especially nervous system and immune cells show a very high
abundance and diversity of sialoglycoconjugates on their cell surface. For
example, the concentration of Sias within the glycocalyx of lymphocytes
has been estimated to be 110 mM (Collins et al., 2004), while overall, the
CNS has the highest concentration of Sias in the body (Schnaar
et al., 2014). However, knowledge on the exact Sia levels of different
human brain cells is incomplete. In general, the glycosylation pattern of
the glycocalyx regulates various functions within the local microenviron-
ment, such as the folding, turnover, trafficking, and signaling of proteins
within the cell membrane (as reviewed in Liao, Klaus, & Neumann, 2020)
and impaired glycosylation can lead to neurodegenerative diseases (see
Box 1). The specific function of each glycan is usually determined by the
outermost sugars, which in mammals is mainly Sia.
Box 1. Sialylation as checkpoint in Alzheimer's
disease
Alzheimer's disease (AD) is the most common neurodegener-
ative disease and leads to dementia in the elderly people. AD
is characterized by memory loss and difficulties with thinking,
problem solving and language and ranges in severity from
mild to later very severe stages. The main neuropathological
features are extracellular deposits of amyloid-β (Aβ), intra-
neuronal tangles composed of hyperphosphorylated forms of
the tau protein and dysmorphic microglia. Genome-wide
association studies have highlighted microglial genes includ-
ing SIGLEC-3 (Hollingworth et al., 2011; Malik et al., 2013;
Naj et al., 2011) and SIGLEC-11 (Bellenguez et al., 2020) as
well as components of the complement system such as CR1
(Harold et al., 2009; Hollingworth et al., 2011; Lambert
et al., 2009), and FH (Zhang et al., 2016) among the major risk
factors of AD. In parallel, more and more evidence arises that
sialylation plays an important role in AD. Protein studies on
cerebrospinal fluid (Hajjar, Liu, Jones, & Uppal, 2020), serum
(Maguire et al., 1994), and postmortem brain tissue
(Maguire & Breen, 1995) of AD patients have revealed
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decreased protein sialylation and a decrease in enzymes
responsible for protein sialylation.
Sialylation serves as a checkpoint that can protect the
removal of cellular structures like synapses and neurons. An
impaired or insufficient sialylation enables aggregation of
proteins like Aβ and phosphorylated tau as seen in the
disease-affected muscles of patients diagnosed with GNE
myopathy (Argov & Yarom, 1984; Murakami, Ihara, &
Nonaka, 1995; Muth, Barthel, Bähr, Dalakas, &
Schmidt, 2009; J. Schmidt et al., 2012). Furthermore, loss of
Sia or desialylation is seen as a molecular sign of protein
aging (Grozovsky et al., 2014; Li et al., 2015; Mehdi, Singh, &
Rizvi, 2012; Qiu et al., 2016; Yang et al., 2015), and proper
desialylation seems to be essential for a correct degradation
of the amyloid protein precursor (APP; Annunziata
et al., 2013) and thus, for prevention of Aβ accumulation in
the cell.
F IGURE 1 The sialic acid cycle from production, to cell surface expression, removal by desialylation, uptake, lysosomal digestion and reuse.
N-Acetylneuraminic acid (Neu5Ac) can be synthesized de novo in the cytosol from uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) in
four different reactions. The first two rate-limiting steps are catalyzed by the glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine
kinase (GNE). The following steps are mediated by N-acetylneuraminic acid synthase (NANS) and N-acetylneuraminic acid phosphatase (NANP).
In the nucleus Neu5Ac is activated with a cytidine monophosphate residue (CMP) by the CMP-sialic acid synthetase (CMAS). Activated Neu5Ac
gets transported into the Golgi apparatus. Here, sialoglycoconjugates are formed by the transfer of the activated sialic acid molecule onto a
glycoconjugate by a sialyltransferase (ST). Glycoconjugates are then transported to their target membrane to form the glycocalyx. On the
glycocalyx, either the terminal sialic acid residues of sialylated glycostructures can be cleaved by neuraminidases (NEU) or the complete sialylated
glycoconjugate can be shed. While sialylated GPI-anchored proteins are cleaved by phospholipases, the sialylated transmembrane proteins are
cleaved by metalloproteinases (scissor). Soluble cleaved or shed sialylated glycostructures or sialooligosaccharides are recognized by sialic acid-
binding immunoglobulin-like lectin (SIGLEC) that can trigger cellular uptake of the structures by endocytosis. Thus, Neu5Ac of
sialoglycoconjugates can be recycled via the endosomal-lysosomal pathway. NEU can cleave off Neu5Ac for reuse in the sialic acid cycle. ADP,
adenosine diphosphate; ATP, adenosine triphosphate; CMAS, CMP-sialic acid synthethase; CMP, cytidine monophosphate; CTP, cytidine
triphosphate; Fuc, fucose; Gal, galactose; GalNAc, N-acetylgalactosamine; Glc, glucose; GlcNAc, N-acetylglucosamine; GNE, glucosamine-
2-epimerase/N-acetylmannosamine kinase; Man, mannose; ManNAc, N-acetylmannosamine; NANP, N-acetylneuraminic acid phosphatase;
NANS, N-acetylneuraminic acid synthase; NEU, neuraminidase; Neu5Ac, N-acetylneuraminic acid; PEP, phosphoenolpyruvic acid; Pi (or PPi),
activated phosphate(s); SIGLEC, sialic acid-binding immunoglobulin-like lectin; ST, sialyltransferase; UDP, uridine diphosphate
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The abnormal accumulation of Aβ and neurofibrillary
tangles seen in AD are also associated with increased oxida-
tive stress in the brain that is normally counterbalanced by
microglial SIGLEC expression (Claude, Linnartz-Gerlach,
Kudin, Kunz, & Neumann, 2013; Schwarz et al., 2015). In
addition, oxidative stress seems to be a general contributor
to aging, and not only to AD.
Thus, the Sia-complement axis as well as the Sia-
SIGLEC axis and their fine-tuned regulation in both direc-
tions are of major interest for future therapy developments
in age-related neurodegenerative diseases like AD.
Most Sias in the brain are found on sialoglycolipids called ganglio-
sides (as reviewed in Schnaar et al., 2014). There are more than
60 known subtypes of gangliosides, differing in the position and num-
ber of Sias linked. The major ganglioside of the mammalian brain is
GM1, with GD1a, GD1b, and GT1b expressed to a lesser degree
(Schnaar et al., 2014). All four of these gangliosides share an identical
tetra-saccharide core with varying amount of mono- or di-Sias
attached to a Gal residue. Brain gangliosides have a variety of func-
tions such as maintaining axon and myelin integrity (Sheikh
et al., 1999) and regulating neuronal transmission (Schnaar
et al., 2014; Takamiya et al., 1996). Cis interactions of gangliosides
(on the same cell surface) are involved in the proper formation of lipid
rafts, while trans interactions (between cell surfaces) may mediate
binding to Sia-recognizing receptors like sialic acid-binding
immunoglobulin-like lectins (SIGLECs).
PolySia is crucial for the development and function of the nervous
system. It is involved in the regulation of synaptogenesis, neuro-
genesis, cell proliferation and migration, cell adhesion and axon guid-
ance and modulates innate immune functions. Particularly, polySia
plays an important role in learning and memory (as reviewed in
Hildebrandt & Dityatev, 2013; Schnaar et al., 2014). Additionally,
polySia binds and buffers neurotrophic factors, growth factors, neuro-
transmitters and cytokines (Sato & Kitajima, 2013; Sumida
et al., 2015). For example, brain-derived neurotrophic factor (BDNF),
which is locally produced and released in the CNS, is retained in the
extracellular matrix bound to polySia under normal conditions
F IGURE 2 Sialic acids (Sias) play a unique role in the glycosylation pattern of the cellular glycocalyx. The sugar chains of cell surface
glycoproteins and glycolipids, together with crosslinking proteoglycans, are collectively known as the glycocalyx. The diverse glycosylation pattern
of the glycocalyx can fulfill a variety of functions within the local environment, such as protein folding and protein stability within the cellular
membrane, protein trafficking, or protein signaling. Due to the unique position of sialic acid residues as terminal caps of glyco-proteins and -lipids
and their negative charge, Sias can form a hydrophilic reservoir that can trap soluble factors like the locally produced brain-derived neurotrophic
factor (BDNF) or the chemokine CCL21. Furthermore, Sias (such as Neu5Ac) can be recognized by receptors (e.g., sialic acid-binding
immunoglobulin-like lectin, SIGLEC), proteins (e.g., complement factor H, FH) or be involved as ligands in cell–cell interaction. Alternatively, Sias
can be removed by neuraminidase (NEU), enabling binding of galectin-3 and other proteins to the exposed galactose (Gal) residues. In turn, Gal
can be removed by beta galactosidase (βGal), enabling binding of collectins, such as mannose-binding lectin (MBL). Free Sia can help to scavenge
reactive oxygen group possibly by hydrolysis or structural alterations in Sia. βGal, beta galactosidase; BDNF, brain-derived neurotrophic factor;
CCL21, CC-chemokine ligand 21; FH, complement factor H; Gal, galactose; Glc, glucose; GlcNAc, N-acetylglucosamine; Man, mannose; NEU,
neuraminidase, Neu5Ac, N-acetylneuraminic acid; polySia, polysialic acid; ROS, reactive oxygen species; SIGLECS, sialic acid-binding
immunoglobulin-like lectins
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(Figure 2). However, under inflammatory conditions BDNF can be
released via the removal of polySia on microglia by the sialidase NEU1
(Sumida et al., 2015). As mentioned before, polySia plays an important
role during brain development. It is detectable from embryonic day
9.5 onwards and reaches peak level just before birth. After birth, poly-
Sia expression is strongly reduced in most brain regions, but is still
detectable on synapses during adulthood (Sato & Kitajima, 2019), as
well as in the neurogenic zones of the hippocampus and dental gyrus
(K. Angata et al., 2004) and the whole retina (Karlstetter et al., 2017).
α2,8-Linked polySia is mainly (85%) attached to neural cell adhesion
molecule (NCAM; Sato & Kitajima, 2013) but is also found on other
glycoconjugates such as synaptic cell-adhesion molecule (SynCAM;
Galuska et al., 2010), neuropilin-2 (Curreli, Arany, Gerardy-Schahn,
Mann, & Stamatos, 2007), and E-selectin ligand 1 (Thiesler,
Beimdiek, & Hildebrandt, 2020; Werneburg et al., 2016). Poly-
sialylated NCAM is present on microglia (Sumida et al., 2015), while
polysialylated neuropilin-2 and E-selectin ligand 1 are restricted to the
Golgi compartment of murine microglia and human THP-1 macro-
phages (Thiesler et al., 2020; Werneburg et al., 2016). Polysialylated
neuropilin-2 and E-selectin ligand 1 can be translocated to the cell
surface and released in the extracellular space by ectodomain shed-
ding upon lipopolysaccharide (LPS) stimulation (Thiesler et al., 2020;
Werneburg et al., 2016).
The sugar chains of cell surface glycoproteins and glycolipids,
together with crosslinking proteoglycans, are collectively known as
the glycocalyx, which forms a sugar coating and hydrophilic cloud over
the surface of all mammalian cells (Figure 2). The terminal sugar resi-
due of the glycoproteins and glycolipids is normally Sia, which consti-
tutes the main negative charge of the cell surface. Sias from the
glycocalyx can be recycled via uptake of sialoglycoconjugates. There
is a continuous turnover of sialoglycoconjugates within lysosomes,
releasing free sialic acid for reuse. The removal of Sias from the
glycoconjugates is called desialylation and can be mediated by
sialidases (as reviewed in Wei & Wang, 2019). Sialidases are glycoside
hydrolase enzymes that remove terminal Sias from glycoproteins and
glycolipids (Figure 1) and are the main mediators of desialylation
(Schnaar et al., 2014; Wei & Wang, 2019). Humans and related mam-
mals have several specific sialidases named neuraminidases (N-acetyl-
alpha-neuraminidase 1–4; NEU1–NEU4; Pshezhetsky &
Ashmarina, 2018; Wei & Wang, 2019). NEU1 is present at the plasma
membrane and in the lysosome. NEU2 is found in the cytosol, NEU3
on the plasma membrane and NEU4 on internal membranes. Both
NEU1 and NEU4 are active towards oligosaccharides, glycoproteins
and gangliosides, while NEU1 mainly acts on glycoproteins and NEU3
shows preferential activity towards gangliosides (Pshezhetsky &
Ashmarina, 2018). In addition, desialylation or loss of Sia recognition
may be a consequence of Sias scavenging reactive oxygen species
(Eguchi et al., 2002; Goswami, Nandakumar, Koner, Bobby, &
Sen, 2003; Iijima, Takahashi, Namme, Ikegami, & Yamazaki, 2004).
Due to their multiple hydroxyl-groups and high local concentration on
the glycocalyx, Sias can be released and thereby scavenge reactive
oxygen species (Figure 2), possibly leading to hydrolysis or structural
alteration of Sias. Finally, Sias are spontaneously hydrolysed from the
glycocalyx at a low rate, which is enhanced in an acidic environment
(Manzi, Higa, Diaz, & Varki, 1994). Loss of Sia on proteins has been
regarded as a sign of molecular aging, often leading to the removal of
the underlying desialylated structure, for example mediating the turn-
over of blood cells and platelets (Grozovsky et al., 2014; Li
et al., 2015; Mehdi et al., 2012; Qiu et al., 2016).
The presence of Sias has been shown to contribute to micro-
domain formation, cell adhesion, tissue homeostasis, cell migration,
chemokine sensing, and growth factor retention (Bassagañas, Pérez-
Garay, & Peracaula, 2014; Kelm, Schauer, Manuguerra, Gross, &
Crocker, 1994; Kiermaier et al., 2016; Lübbers, Rodríguez, & van
Kooyk, 2018; Möckl, Horst, Kolbe, Lindhorst, & Bräuchle, 2015; Sato &
Kitajima, 2019; Varki & Gagneux, 2012). Furthermore, Sias are
involved in the transport of micro- and macromolecules and can pre-
vent receptor binding by masking underlying structures or the recep-
tor itself (as reviewed in Schauer, 2000). Most of the observed effects
of Sias may be related to its unique position as the terminal monosac-
charide cap of the cell surface sugar chains and its negative carboxyl
moiety with a pKa of 2.6 for Neu5Ac (Eylar, Madoff, Brody, &
Oncley, 1962). Sias, especially polySias, contribute strongly to the
negative charge and hydrophilic nature of the cell surface (Figure 2),
and polySias bind and buffer soluble factors, including neurotrophins,
growth factors and neurotransmitters (Sato & Kitajima, 2013). The
affinity of proteins for sugar residues is normally relatively low, thus
often requiring multiligand interactions between several
sialoconjugates and the target structures (Cohen & Varki, 2014;
Dam & Brewer, 2010). However, several receptors and other proteins
of the innate immune system have been shown to specifically interact
with cell-surface Sias, serving as a checkpoint for regulating the innate
immune system. The mechanisms of this Sia sensing are discussed in
more detail below.
3 | SIA SENSING BY THE COMPLEMENT
SYSTEM
Sias can inhibit complement activation by modulating key functions of
the complement system during immune surveillance and homeostasis.
The complement system can be activated by three different pathways,
the (a) classical, (b) lectin, and (c) alternative pathway (as reviewed in
details by Ricklin, Hajishengallis, Yang, & Lambris, 2010). All three
pathways have distinct initial triggers, but merge on C3 activation
before triggering distinct effector pathways. For activation of C3, the
inactive C3 protein is cleaved by a C3-convertase into the functional
complement component 3a (C3a), complement component 3b (C3b)
and other signaling fragments (e.g., iC3b). Whereas C3a attracts and
activates immune cells, C3b (and its derivative the inactive form iC3b)
acts as an opsonin to tag any nearby structures for phagocytosis
(Merle, Church, Fremeaux-Bacchi, & Roumenina, 2015). In contrast to
the classical and lectin pathway, the trigger of the alternative pathway
is based on the spontaneous hydrolysis of an internal thioester bond
of C3 that occurs continually at a low level during normal physiologi-
cal conditions and initiates the mainly solvent-based C3-convertase
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(C3H2OBb) that cleaves C3 into C3a and C3b (Ricklin et al., 2010).
Subsequently, C3b reacted with a foreign membrane can bind to
cleaved complement factor B (Bb) to form a stable alternative path-
way C3-convertase (C3bBb). As a consequence, the alternative path-
way may contribute to the other two pathways by amplifying the
cleavage and activation of C3 additionally and thus, appears to be
involved in up to 90% of all complement activation events (Harboe &
Mollnes, 2008). Therefore, the alternative pathway is highly regulated
to avoid inappropriate damage to host tissues. The complement pro-
tein properdin can act on cell surfaces as initiator of the alternative
pathway and in addition as an activator of C3 by stabilizing the alter-
native pathway C3-convertase (C3bBb) and forming a complex
(C3bBbP). In contrast, the complement factor H (FH) competes with
complement factor B (FB) to bind C3b in order to inhibit the formation
of C3bBb and thus, negatively regulates the alternative pathway
(Figure 3). FH also dissociates pre-existing C3-convertases (C3bBb)
and attracts complement factor I (FI) to degrade C3b (Xue
et al., 2017).
Recent research demonstrated that sialylation is critical for
protecting fetal extraembryonic tissue from maternal complement
attack involving C3 (Abeln et al., 2019). The exact mechanism for the
fetal protective effect of Sias is still unclear and might be explained by
several findings. In line with this protection, we recently showed that
the absence of C3 rescued the synapse and neuronal loss in mice with
reduced glycocalyx sialylation (Klaus et al., 2020). Free Sia has been
shown to inhibit activation of C3 and the following complement cas-
cade (Fujita et al., 1999). However, relatively high concentrations of
free Sia were needed to observe this effect, questioning whether sol-
uble Sia is responsible for the in vivo complement inhibition. More
importantly, FH can bind Sias and is a well-known inhibitor of the
alternative C3-convertase, as described before. In total, FH has at
least three binding sites for polyanions such as Sias, located in the
F IGURE 3 Sialic acid—complement interactions on intact versus altered glycocalyx. (a) Intact glycocalyx with normal sialylation: Under
physiological conditions, the regulatory complement factor H (FH) can bind to sialic acids (Sia) of the host cell glycocalyx and competitively
prevent binding of complement factor B (FB) to C3b. Thus, FH can inhibit the formation of the alternative C3-convertase (C3bBb) and
consequently inhibits the activation of the alternative complement pathway on cells with an intact glycocalyx. Likewise, soluble polysialic acid
(polySia) has been shown to inhibit the activation of the alternative complement pathway, for example, possibly via binding to the cationic protein
properdin. (b) Altered glycocalyx with reduced sialylation: Properdin (P) binds to lesioned or altered cells (e.g., in the absence of sialic acid
residues), that promotes C3b relocation to this site. It stabilizes the formation and activation of the alternative C3-convertase (C3bBb), together
with the complement activator properdin (C3bBbP). Furthermore, lesioned or altered cells (e.g., in the absence of sialic acid residues) are
opsonized by C1q, a subunit of the C1qC1r2C1s complex (C1). The “inactivated” C1 becomes activated (C10) leading to a cascade with classical
C3-convertase (C4b2b) activation, here only shown as dashed arrow. The classical C3-convertase then cleaves C3 into C3b and C3a. Weak
binding of C3b on altered cells without FH binding could lead to further recruitment of FB activated by complement factor D (FD) and
subsequently to the amplification of the complement pathway by the alternative C3-convertase (C3bBb). Thus, loss or removal of sialic acids
(shown here as scissor) by neuraminidases, oxidative damage or aging triggers classical and alternative complement activation, facilitates C3b
activation and the formation of the classical and alternative C3 convertases, which leads to an amplifying complement activation loop (red arrow).
Bb, fragment of cleaved complement factor B; C1, C1qC1r2C1s complex; C3, complement component 3; C3a, fragment of cleaved complement
component 3; C3b, fragment of cleaved complement component 3; ECM, extracellular matrix; FD, complement factor D; FB, complement factor
B; FH, complement factor H; polySia, polysialic acid; P, properdin; Sia, sialic acid
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region CCP 7, CCP 9–15, CCP 19–20, while the region CCP 19–20
was found to be key for FH interactions with sialylated host surfaces
(summarized in detail by Ferreira, Pangburn, & Cortés, 2010). Impor-
tantly, FH only binds to α2,3-linked Sia residues of oligosaccharides
typically attached to cell surfaces, but not soluble Sia monosaccha-
rides (Schmidt et al., 2018). When FH binds to α2,3-linked Neu5Ac on
the glycocalyx, it forms the active C3b–FH–Sia complex that inhibits
the formation of the alternative C3-convertase (Figure 3a; Blaum
et al., 2015). On the other hand, in the absence of Sia the underlying
structures can be leading to classical complement pathway activation.
Here, the desialylated cell surface structures are recognized by the
complement complex C1 (C1qC1r2C1s), triggering a complement cas-
cade response via opsonization and formation of a C4b2b complex,
the classical pathway C3-convertase. Again, absence of FH locally
bound to cell surface sialic acid residues additionally could amplify the
C3 activation via the alternative pathway C3-convertase (C3bBb).
Thus, Sia residues of the glycocalyx are probably the critical determi-
nants for classical and alternative complement pathway inhibition. Of
note, the lectin pathway of complement activation also appears to be
prevented by sialylation as Sias inhibit binding to cells of the
mannose-binding lectin (MBL), the main initiator of the lectin pathway
(Saevarsdottir, Vikingsdottir, & Valdimarsson, 2004).
FH gene variants can cause age-related macular degeneration
(AMD), the main genetic cause of blindness (Ferreira et al., 2010).
Two-year-old FH-deficient (Cfh−/−) mice showed an accumulation of
complement C3 in the neural retina, together with a decrease in
electron-dense material, thinning of Bruch's membrane, changes in
the cellular distribution of retinal pigment epithelial cell organelles,
and disorganization of rod photoreceptor outer segments (Coffey
et al., 2007), but it is unclear how far this effect is related to Sia-
binding of FH (Toomey, Kelly, Saban, & Bowes Rickman, 2015). Inter-
estingly, aged FH-deficient mice also show typical features of AD in
the retina with amyloid-β deposition and phosphorylated tau accumu-
lation in the choroidal vessels associated with the retinal degeneration
(Aboelnour, Kam, Elnasharty, Sayed-Ahmed, & Jeffery, 2016). Further-
more, FH appears to be a risk factor for AD in the Chinese population
(Zhang et al., 2016). Mutations in the binding domain of FH prevents
its ability to inactivate C3 by either disassembling the alternative
pathway C3-convertase or supporting FI in its ability to degrade C3b
(Ferreira et al., 2010). Similarly, mutations in complement receptor
1 (CR1, an AD risk gene, FI co-factor and complement regulator,
Hourcade, Kathryn Liszewski, Krych-Goldberg, & Atkinson, 2000)
enhanced binding of CR1 to C3b (Fonseca et al., 2016), which might
increase microglial phagocytosis of synapses and neurons. Thus, there
may be a link between dysfunctional complement regulation and AD
(see Box 1, but an imbalance of Sias as regulators of the complement
system was only recognized recently in the prodromal state of AD
(Hajjar et al., 2020).
FH gene variants causing AMD potentially interfere with binding
of FH to polyanions such as Sias, and thus allow uncontrolled comple-
ment deposition and activation followed by neurodegeneration, but
this has not been verified. Recently we found that low molecular
weight α2,8-linked polySia with an average degree of polymerization
of 20 also attenuated alternative complement activation (Figure 3a),
but not classical pathway activation, leading to reduced membrane
attack complex formation and cell lysis in the retina (Karlstetter
et al., 2017). Since FH binds to α2,3-linked Sia, but not α2,6- or
α2,8-linked Sia (C. Q. Schmidt et al., 2018), the mechanism of this
inhibitory effect of low molecular weight polySia on the alternative
pathway remains elusive.
4 | SIA SENSING BY SIGLECS
SIGLECs belong to the class of I-type lectins that are characterized by
three major components: (a) a set of 1–16 immunoglobulin domains
which determine how far the N-terminal head group extends from the
plasma membrane, (b) an extracellular carbohydrate recognition
domain at the N-terminus which may recognize Sia residues on the
glycocalyx of other cells (trans) or on the same cell (cis), and (c) an
intracellular signaling tail. For some SIGLECs, SIGLEC-14, -15, -16 in
humans and SIGLEC-3 and SIGLEC-H in mouse, the intracellular sig-
naling tail contains a positively charged amino acid residue that can
associate with activating adaptor proteins such as TYROBP/DAP12
bearing an immunoreceptor tyrosine activation motif (ITAM; Figure 4;
Duan & Paulson, 2020). Upon ligand binding, such ITAM-containing
adaptor proteins are recruited and become phosphorylated by a mem-
ber of the spleen tyrosine kinase (SYK) family triggering a number of
downstream signaling cascades similar as for other ITAM-SYK-
signaling receptors like complement receptor 3 (CR3) or triggering
receptor expressed on myeloid cells 2 (TREM2; as reviewed in
Linnartz-Gerlach, Kopatz, & Neumann, 2014).
However, most SIGLEC receptors contain an intracellular
immunoreceptor tyrosine-based inhibition motif (ITIM; Figure 4),
which upon Sia binding lead to inhibitory downstream signaling path-
ways. Besides conserved SIGLEC-2, these SIGLECs include SIGLEC-E,
-F and -G in mice and SIGLEC-3, -5, -6, -7, -8, -9, -10, -11, and -12 in
humans (Duan & Paulson, 2020). Upon ligand binding to extracellular
Sia residues, these SIGLECs containing intracellular ITIMs can coun-
teract activatory signals emanating from receptors containing
ITAMs (Crocker, Paulson, & Varki, 2007). The counteraction is initi-
ated via phosphorylation of ITIMs by Src family kinases after ligand
binding. The tyrosine-phosphorylated ITIMs then recruit tyrosine
phosphatases, such as Src homology region 2 domain-containing
phosphatase-1 (SHP-1/PTPN6) or Src homology region 2 domain-
containing phosphatase-2 (SHP-2/PTPN11) (as reviewed in Duan &
Paulson, 2020), which may dephosphorylate signaling molecules in
the ITAM-signaling cascade of associated activatory receptors to
suppress the activation of immune cells (Linnartz, Wang, &
Neumann, 2010).
The ITAM-SYK-signaling pathway of TREM2/DAP12 or
CR3/DAP12 (Figure 4b) induces phagocytosis in mononuclear phago-
cytes such as microglia. Multiple studies have shown how ITIM signal-
ing of inhibitory SIGLECS could modulate this pathway. One study
showed that SIGLEC-5 inhibited macrophage-mediated phagocytosis
of apoptotic bodies upon binding of sialooligosaccharide ligands or
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monoclonal antibodies (Rapoport, Sapot'ko, Pazynina, Bojenko, &
Bovin, 2005). Another study discovered that SIGLEC-11 was able to
prevent microglial phagocytosis of apoptotic neuronal material and to
attenuate LPS-induced inflammation (Wang & Neumann, 2010). In
addition mouse SIGLEC-E prevented the removal of neural debris and
the phagocytosis-associated oxidative burst of microglia (Claude
et al., 2013). Interestingly, most inhibitory SIGLECs act as endocytic
receptors after binding of small sized sialoglycoconjugates, while they
inhibit phagocytosis of larger structures (Duan & Paulson, 2020).
Beside inhibition of phagocytosis, the inhibitory ITIM-containing
SIGLECs may also inactivate the inflammasome via inhibiting SYK sig-
naling triggered by ITAM-signaling receptors. It is reported that both
c-Jun NH2-terminal protein kinase (JNK) and SYK are necessary
kinases for inflammasome activation (Linnartz & Neumann, 2013).
Toll-like receptor (TLR) signaling contributes to the JNK kinase activa-
tion, whereas ITAM receptors stimulate SYK kinase. Thus, inhibitory
SIGLECs may also prevent inflammatory activation of mononuclear
phagocytes. There is evidence in B-cells that ligand binding sequester
inhibitory SIGLECs away from activatory receptors, thus increasing
the signaling effect of the activatory receptors (Duan &
Paulson, 2020). However, so far this phenomenon has not been
observed for microglial cells.
SIGLECs are mainly expressed on immune cells, such as
microglia, macrophages and monocytes with a few exceptions, such
as for SIGLEC-4 (expressed in oligodendrocytes and Schwann cells)
and SIGLEC-6 (also expressed in placental trophoblasts) as nicely
summarized by Duan and Paulson (2020). All inhibitory SIGLECs
expressed on microglia including mouse SIGLEC-2, human
SIGLEC-3, SIGLEC-11, mouse SIGLEC-E, and SIGLEC-F have trans
interaction with Sia residues on neighboring cells and several
SIGLECs including SIGLEC-3 and SIGLEC-E have been demon-
strated to also bind Sia residues in cis (Figure 4a; Bornhöfft,
Goldammer, Rebl, & Galuska, 2018).
The first functional studies on human SIGLEC-11 were carried out
by ectopic expression of this human receptor on murine microglia
(Wang & Neumann, 2010). The expression of SIGLEC-11 was able to
F IGURE 4 Sialic acid—SIGLEC interactions on intact versus altered glycocalyx. (a) Intact glycocalyx with normal sialylation: Sialic acids (Sia) on
the intact glycocalyx can be sensed by SIGLEC receptors on the same cell (cis) and on other cells (trans). Inhibitory SIGLEC receptors such as
SIGLEC-2/-3/-11 (human) and SIGLEC-E/-F (mouse) have an immunoreceptor tyrosine-based inhibition motif (ITIM) that upon ligand binding
recruit phosphatases (such as SHP1/2) that can terminate intracellular signals emanating from immunoreceptor tyrosine-based activation motif
(ITAM) signaling receptors via their intrinsic phosphatase activity. Thus, the ITIM signaling pathway inhibits several responses of microglia
including phagocytosis, oxidative burst, migration, proliferation and inflammation and can down-regulate inflammasome activation. (b) Altered
glycocalyx with reduced sialylation: Stressed or lesioned cells show desialylated glycoconjugates on their glycocalyx that can be opsonized by C1q
within the C1 complex, which becomes activated (C10). This initiates the formation of the C3-convertase that cleaves C3 into C3a, C3b and its
downstream signaling fragment iC3b. The iC3b fragment binds to complement receptor (CR3) of microglia and activates the microglial cells via
the ITAM of TYROBP/DAP12. Furthermore, other ITAM-signaling receptors of microglia such as TREM2 recognize aminophospholipids such as
phosphatidylserine (PS) that are externalized and accessible after enzymatic removal or loss of the negatively charged sialic acids. The activatory
receptors cannot be silenced by inhibitory SIGLEC receptors that fail to sense sialic acids on the altered glycocalyx of the lesioned cell. C10 ,
“activated” C1 complex; CR3, complement receptor 3 as heterodimer of CD11b/ITGAM and CD18/ITGB2; iC3b, soluble C3 signaling fragment;
ITAM, immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor tyrosine-based inhibition motif; PS, phosphatidylserine; Sia, sialic
acid; SIGLEC, sialic acid-binding immunoglobulin type lectin; TREM2, triggering receptor expressed on myeloid cells 2
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inhibit the proinflammatory response of LPS-challenged microglia and
prevented microglial phagocytosis of apoptotic neuronal material. This
neuroprotective effect of SIGLEC-11 was mediated by trans interac-
tion with polySia on neighboring neurons, but not by cis interaction
with its own glycocalyx (Wang & Neumann, 2010). Similar neuro-
protective effects were shown for SIGLEC-E (Claude et al., 2013).
SIGLEC-E inhibited the phagocytosis of neural debris. Furthermore,
SIGLEC-E on microglia prevented the neural debris-triggered release
of superoxide and production of proinflammatory cytokines. Although
on a low level cis interaction can be found for SIGLEC-E, our data indi-
cated that the neuroprotective role of SIGLEC-E was mediated in
trans via recognition of Sia residues on neurons (Claude et al., 2013).
Interestingly, the release of the microglia-intrinsic polySia pool from
Golgi upon inflammatory stimulation acted as a trans-activating ligand
of SIGLEC-E, thus inhibiting the inflammatory response in traumatic
brain injury (Thiesler et al., 2020). In contrast, CRISPR/Cas9-mediated
Siglec-E knockout of the murine microglial cell line BV2 resulted in a
more pronounced increase of LPS-induced proinflammatory cytokines
on transcription level. Furthermore, Siglec-E knockout of BV2
prevented the anti-inflammatory effect of exogenously added polySia
(Thiesler et al., 2020).
Both neurodegeneration and aging have been associated with
dysfunction or deletion of SIGLEC receptors (Duan &
Paulson, 2020; Schwarz et al., 2015). SIGLEC receptors on micro-
glial cells interact with Sia to inhibit microglial activation, inflam-
mation, phagocytosis and oxidative burst (Figure 4a). Siglec-E KO
mice showed oxidative damage to cellular DNA, proteins and lipids
in all organs that was related both to an unbalanced ROS metabo-
lism, and to a secondary impairment in detoxification of reactive
molecules (Schwarz et al., 2015). Consequently, Siglec-E KO mice
exhibited accelerated aging and their life span was reduced
(Schwarz et al., 2015). Interestingly, an opposite phenotype was
observed after deletion of the crucial activatory microglial TREM2
receptor (Linnartz-Gerlach et al., 2018). Deletion of the main
counter-balancing activatory TREM2 receptor in mice led to
decreased age-related inflammatory signs and reduced neuronal
loss in the substantia nigra and the hippocampus of 24 months old
mice (Linnartz-Gerlach et al., 2018). The absence of age-related
neurodegeneration in Trem2 KO mice was associated with
decreased microglial numbers and less accumulation of oxidized
lipids (Linnartz-Gerlach et al., 2018).
Meanwhile, it also has been shown that human SIGLEC-3 pre-
vents microglial uptake of amyloid-β 42 (Aβ42) (Griciuc et al., 2013).
Human SIGLEC-3, also known as CD33, is abundantly expressed on
microglia. In contrast to other SIGLECs, SIGLEC-3 is capable to inter-
act with Sia in both trans and cis. Two splice variants of human CD33
are relevant for AD: the full-length CD33M isoform and the shorter
CD33m isoform, which lacks the exon 2-encoded Sia ligand-binding
domain (Malik et al., 2013). Several genome-wide association studies
(GWAS) indicated that the full length CD33M is a risk factor for AD,
whereas a decreased AD risk was associated with the shorter CD33m
isoform (Malik et al., 2013). Furthermore, increased expression of
CD33M was detected in microglial cells of AD brains, further
supporting the GWAS findings (Hollingworth et al., 2011; Naj
et al., 2011). Interestingly, the phagocytosis of Aβ42 by microglia was
inhibited with increasing human CD33M levels. Concomitantly, the
Aβ pathology was attenuated in amyloid precursor protein (APP)-
transgenic mice by inactivating CD33, and thus possibly increasing
the uptake of Aβ42 (Bradshaw et al., 2013; Griciuc et al., 2013). These
data suggest that any weakening of the Sia-SIGLEC-3 axis, either by
desialylation or variants of SIGLEC-3/CD33m lacking the Sia-binding
domain might increase microglial phagocytosis of Aβ42, and hence
potentially could be beneficial in AD pathology (see Box 1). Impor-
tantly, the human and the mouse SIGLEC-3 share the same name but
not the exact same function. While the human SIGLEC-3 is an inhibi-
tory receptor with an ITIM domain, the mouse SIGLEC-3 has only an
ITIM-like domain. Consequently, both receptors fulfill different func-
tions as shown previously (Bhattacherjee et al., 2019). While the
human SIGLEC-3 inhibits monocyte and microglial phagocytosis, no
effect on phagocytosis was found for the mouse SIGLEC-3
(Bhattacherjee et al., 2019).
Most recently, it was reported that SIGLEC-2, also called CD22,
downregulates microglial phagocytic ability during aging and
SIGLEC-2 blockade promotes removal of α-synuclein fibrils, Aβ oligo-
mers and myelin debris in vivo (Pluvinage et al., 2019). Furthermore,
SIGLEC-2 was upregulated in microglia during aging (Pluvinage
et al., 2019), and in the brains of AD patients (Friedman et al., 2018).
By activating CD22 with synthetic glycopolymers bearing α2–6-linked
Sia, it was shown that SIGLEC-2 on microglia inhibited phagocytosis
(Pluvinage et al., 2019). Interestingly, inhibition of SIGLEC-2 with
SIGLEC-2 blocking antibody or genetic ablation showed the opposite
effect and increased the phagocytosis of Aβ oligomers, myelin debris
and α-synuclein fibrils in vivo. Long-term blockade of SIGLEC-2 using
blocking antibody of SIGLEC-2 via CNS-delivery was even able to
restore microglial homeostasis and to attenuate the cognitive decline
of aged mice (Pluvinage et al., 2019).
5 | EFFECTS OF HYPERSIALYLATION OR
DECREASED NEURAMINIDASE ACTIVITY
Cancer cells often misuse Sias as checkpoint to escape the immune
control. Therefore, cancer cells typically have increased expression of
different sialyltransferases, leading to increased Sia levels and
increased incorporation of sialoconjugates into the glycocalyx of their
cell membrane (Duan & Paulson, 2020; Rodrigues & Macauley, 2018).
Interestingly, some bacteria can exploit this self-recognition sys-
tem by incorporation of Sias into their own capsule, thus masking
their antigenic cell surface and escape the immune surveillance. They
may acquire Sia via sialidase-mediated removal from host tissue or via
de novo generation of Sias as molecular camouflage to escape
immune defense. Several bacteria also produce polySia by themselves
and thus escape host immune attack via inactivating complement sys-
tem and silencing innate immune cells via SIGLEC-11. For example,
the polySia capsule of Escherichia coli K1 (E. coli K1) inhibits alternative
complement pathway activation (Pluschke, Mayden, Achtman, &
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Levine, 1983) and engages the inhibitor receptor SIGLEC-11 (Schwarz
et al., 2017), while bacteria of serogroup B Neisseria meningitides use
α2,8-linked polySia overexpression to escape elimination by antibody-
dependent classical complement attack in normal human serum
(Kahler et al., 1998).
Impaired or insufficient activity of neuraminidases can be harmful
for the cell. For example, NEU3 and NEU4 are important enzymes in
the lysosomal degradation of gangliosides by removing the Sia resi-
dues (Figure 5). The deficiency of Neu3 and Neu4 in mice resulted in
the accumulation of nondigested ganglioside GM3 in lysosomes of
microglia, vascular pericytes and neurons. Furthermore, this impaired
lysosomal storage resulted in micro- and astrogliosis, neu-
roinflammation, and accumulation of lipofuscin bodies in the mouse
brain (Pan et al., 2017). Thus, the cleavage of terminal Sias is essential
in ganglioside catabolism. Moreover, it is well-known that neuramini-
dase deficiencies within the lysosome leads to accumulation of
undegraded sialoconjugate substrates, leading to neurodegenerative
lysosomal storage diseases (Figure 5). For example, genetic deficiency
of NEU1 in humans causes sialidosis Type 1 and 2 (Pshezhetsky &
Ashmarina, 2018), which triggers severe pathologies in the central
nervous system including retinopathy, ataxia, mental retardation,
myoclonus and seizures (Seyrantepe et al., 2003). NEU1 deficiency
induces over-sialylation of lysosomal-associated membrane protein
1 (LAMP1) that is leading to excessive lysosomal exocytosis
(Yogalingam et al., 2008). Thus, reduced neuraminidase activity causes
both, accumulation of sialylated lipids and proteins in lysosomes, visi-
ble as lipofuscin in neurons and lipid drops in microglia/macrophages,
as well as increased expelled sialylated glycoconjugates that appear as
extracellular protein aggregates or lipid drops (Figure 5).
Of note, APP is normally sialylated and can be desialylated by
NEU1. In the Neu1-deficient mouse, which has impaired desialylation,
hypersialylated APP accumulated in the lysosomes of neural tissue. In
F IGURE 5 Decreased neuraminidase activity leads to lysosomal and extracellular protein and lipid accumulation. (a) The removal of sialic
acids is catalyzed by neuraminidases (NEUs). The degradation of sialoglycoconjugates is an essential step for the reuse or digestion of the lipids
and proteins. In humans four NEUs are known NEU1–4. NEU1–4 show tissue- and compartment-specific preferences and also substrate
specificity. NEU1 is mainly localized at the lysosomal and plasma membranes, whereas NEU2 is mainly found in the cytosol. NEU3 is localized in
the caveolae microdomains or plasma and endosomal membranes, while NEU4 is predominately present in the endoplasmic reticulum membranes
and in the lysosome as well as the mitochondria. Desialylation greatly influences the structure of glycoconjugates and is creating or changing their
binding sites. Furthermore, NEUs contribute to the regulation of various cellular functions, such as lysosomal degradation or exocytosis. For
example, neuraminidase 1 (NEU1) negatively regulates lysosomal exocytosis of by-products by processing the sialic acid residues on the
lysosomal-associated membrane protein 1 (LAMP1). (b) Deficiency in NEU1 (NEU1−/−) is leading to accumulation of sialylated lipids and proteins
in the lysosome, visible as lysosomal swelling or lipofuscin accumulation. In Neu1−/− mice, oversialylated amyloid precursor protein (APP) was
accumulated in the lysosomes of neurons. Furthermore, the deficiency in removal of sialic acid residues from the lysosomal protein LAMP1
increased the exocytosis of undegraded proteins like APP to the extracellular space, thus, supporting Aβ aggregation. (c) NEU3 and NEU4 are very
important in the processing and degradation of gangliosides in the central nervous system. In NEU3/NEU4-deficient mice (Neu3−/-Neu4−/−), the
ganglioside GM3 was not properly degraded and was accumulated in lysosomes of microglia, vascular pericytes and neurons. This resulted not only
in decreased levels of gangliosides, but also in micro- and astrogliosis, cognitive impairment and lipofuscin body accumulation
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an AD mouse model overexpressing the human mutant APP an addi-
tional ablation of Neu1 accelerated Aβ production that was leading to
excessive lysosomal exocytosis of amyloid-β peptides into the extra-
cellular space (Annunziata et al., 2013). Plaque load was reversed in
this mouse model by enforced overexpression of NEU1 via injection
of an adeno-associated virus (AAV) containing the human NEU1
(Annunziata et al., 2013). Hence, reduced activity or capacity of NEU1
to digest sialoconjugates in the lysosome may be a risk factor for
developing aggregopathies such as AD.
Interestingly, not only the accumulation of sialoconjugates in lyso-
somes but also in endocytic compartments can impair the degradation
capacity of the lysosomal system (Schmid, Mach, Paschke, &
Glössl, 1999). Accordingly, the bacteria Pseudomonas aeruginosa uses
Sia to indirectly inhibit phagosome maturation in macrophages.
Although the mechanism is not fully understood, the phagosome mat-
uration is probably impaired by sialoconjugates due to reduced
phagosome-lysosome fusion (Mukherjee, Khatua, & Mandal, 2020).
Since the lysosome plays an important role in the degradation and
recycling of extra- and intracellular substances, impaired removal of
Sias and thus accumulation of misfolded proteins might be a potential
target in treating lysosomal storage diseases.
In addition, the composition of Sias is markedly different between
humans and other mammals. As mentioned before, humans can only
produce Sias from Neu5Ac due to a loss-of-function mutation in the
enzyme cytidine monophospho-N-acetylneuraminic acid hydroxylase
(CMAH), while most other mammals including mice produce and
express Neu5Ac and Neu5Gc (Altman & Gagneux, 2019). It is still
unclear whether there is any contribution of the nonhuman Sia type
Neu5Gc to neuroinflammatory or neurodegenerative disease, but
trace amounts of Neu5Gc were found in human tissue, probably
derived from consumed red meat and dairy products (Banda, Gregg,
Chow, Varki, & Varki, 2012; Casadesús et al., 2013). This nonhuman
Sia type can trigger autoantibodies in humans, resulting in the autoim-
munity termed “xenosialitis” (Dhar, Sasmal, & Varki, 2019;
Varki, 2017). Neu5Gc cannot be digested properly by the human
endogenous neuraminidases after incorporation into α2-8-linked
oligo-/polySias (Davies et al., 2012) and this can result in hyper-
sialylation or impaired desialylation.
While insufficient activity or capacity of neuraminidases to digest
sialoconjugates in the lysosome might trigger or promote accumula-
tion of lipid and protein aggregates as seen in AD, none of these signs
were observed in human diseases associated with hypersialylation
such as cancer (Rodrigues & Macauley, 2018).
6 | EFFECTS OF DESIALYLATION OR
INCREASED NEURAMINIDASE ACTIVITY
The removal of the negatively charged Sias by desialylation regulates
multiple cellular functions and pathological processes (Wei &
Wang, 2019). In particular, desialylation regulates brain innate immu-
nity and microglial homeostatic function. We found that various
inflammatory stimuli such as LPS, fibrillar Aβ, or Tau induced a
sialidase activity on the surface of microglial cells, desialylating surface
glycans and maintaining microglial activation in culture (Allendorf,
Puigdellívol, & Brown, 2020). In vivo, exposure of postnatal rats to
LPS induced neuraminidase activity and a long-lasting desialylation of
glycoproteins on neural cells in the CNS (Demina et al., 2018). Fur-
thermore, desialylation in postnatal rat brains was associated with a
primed microglial phenotype and thus might have pathophysiological
consequences in adulthood.
Sialylation of neurons also acts homeostatically on neighboring
cells via SIGLECs (Figure 6). For instance, interaction between ganglio-
sides and SIGLEC-4 (MAG, myelin associated glycoprotein) mediates
myelin stability and inhibits neural sprouting after injury. Conse-
quently, spinal axon outgrowth in rat was enhanced after removal of
Sias by sialidases (Mountney et al., 2010). Furthermore, desialylation
can enhance microglial phagocytosis of neuronal structures via
decreased activation of inhibitory SIGLECS, including SIGLEC-2
(CD22; Pluvinage et al., 2019), SIGLEC-3 (CD33; Bradshaw
et al., 2013), SIGLEC-11 (Wang & Neumann, 2010), and SIGLEC-E
(Claude et al., 2013).
Cell surface receptors can be regulated by sialylation and des-
ialylation of the receptors themselves (Figure 6). Attachment or
detachment of the negatively charged Sias can affect receptor bind-
ing, receptor activity or receptor turnover (Pshezhetsky &
Ashmarina, 2018). Several receptors regulating microglial activation
and phagocytosis are stimulated by desialylation, suggesting the possi-
bility that sialylation of microglial receptors acts as a general “OFF”
switch or immune checkpoint, while desialylation licenses these
immune receptors to operate. Microglial TLR4 was found to be acti-
vated after exposure to sialidases in vitro and in vivo (Allendorf,
Franssen, & Brown, 2020; Fernández-Arjona, Grondona, Fernández-
Llebrez, & López-Avalos, 2019). We found that activation of microglia
by LPS caused Neu1 to translocate to the cell surface and to des-
ialylate TLR4 (Figure 6). Furthermore, microglial activation was
maintained even after LPS was removed, constituting a type of
immune memory (Allendorf, Franssen, et al., 2020). The inflammatory
effects of TLRs can be down-regulated by SIGLECs (Chen
et al., 2014). We could show that SIGLEC-E inhibited microglial activa-
tion by binding sialylated TLR4, and this inflammatory break was
released by desialylation of TLR4 (Allendorf, Franssen, et al., 2020).
Activation of microglia with LPS was also found to cause
Neu1-mediated removal of microglial polySia, leading to release of
BDNF normally bound to polySia (Sumida et al., 2015).
Another important microglial receptor class are integrins that
mediate cell adhesion and phagocytosis. Desialylation of the fibronec-
tin receptor on myeloid cells increased fibronectin binding many-fold
by exposing the binding site (Pretzlaff, Xue, & Rowin, 2000; Semel
et al., 2002). Desialylation of the integrin CR3 increased the binding
to its ligand intercellular adhesion molecule 1 (ICAM-1; Feng
et al., 2011). Moreover, we found that sialidases induced microglial
phagocytosis via CR3 (Allendorf, Puigdellívol, et al., 2020). However, it
is unclear whether microglial CR3 is directly regulated by sialylation or
indirectly via SIGLEC-E binding as occurs in neutrophils (McMillan
et al., 2013).
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Desialylation of cells enables binding of the galactose-binding opso-
nin galactin-3 (Nomura, Vilalta, Allendorf, Hornik, & Brown, 2017).
Galectin-3 can be released by LPS-stimulated microglia (Burguillos
et al., 2015), together with a sialidase (probably NEU1), which can des-
ialylate neighboring cells (Nomura et al., 2017; Figure 6). When des-
ialylation of neurons occurs, galectin-3 binds to uncovered Gal residues
of glycoproteins and glycolipids on neurons, that normally are occupied
by terminal Sias (Figure 2). This galectin-3 binding enhanced the phago-
cytosis of neuronal-like cells by microglia (Nomura et al., 2017). Note
that galectin-3 can activate microglial TLR4 (Burguillos et al., 2015; Yip
et al., 2017), c-mer proto-oncogene tyrosine kinase (MerTK; Nomura
et al., 2017) and TREM2 (Boza-Serrano et al., 2019), but it is not known
whether galectin-3 is specifically binding the desialylated forms of these
receptors. Desialylation of cells also enables the binding of C1q
(Linnartz, Kopatz, Tenner, & Neumann, 2012), calreticulin (Feng et al.,
2018) and mannose binding lectin (Saevarsdottir et al., 2004), which can
promote phagocytosis and complement activation.
As indicated above, Sias inhibit the complement cascade, indicating
that desialylation could activate the complement system (Figure 6). In
vivo, rats treated with neuraminidase were found to have C3 activation
in cerebrospinal fluid, followed by ependymal damage. Ependymal cell
death was provoked after the neuraminidase-mediated removal of the
protective Sia levels from the cell surfaces (Granados-Durán
et al., 2015. in vitro studies indicated that the removal of neurites by
microglia could be induced by desialylation of neurons or microglia
(Allendorf, Puigdellívol, et al., 2020; Linnartz et al., 2012; Linnartz-Ger-
lach, Schuy, Shahraz, Tenner, & Neumann, 2016). When neurons were
desialylated, C1q (a subunit of the C1 complex) and C3 bound to neu-
rites, resulting in CR3-mediated microglial phagocytosis of the neurites
(Figure 6; Linnartz-Gerlach et al., 2016; Linnartz et al., 2012). It is not
clear why C1q binds more to desialylated neurons, but this might be
mediated by C1q binding to pentraxin-3, as it has been shown that des-
ialylation of pentraxin-3 allows C1q binding and complement activation
(Inforzato et al., 2006). We also found that desialylation of microglia
triggered CR3-mediated phagocytosis of neurons in a co-culture system
(Allendorf, Puigdellívol, et al., 2020).
GNE is required for Sia synthesis, and homozygous knockout of Gne
in mice is embryonically lethal (Schwarzkopf et al., 2002), indicating the
F IGURE 6 Effects of desialylation on microglial activation and phagocytosis of neurons. Cell surface receptors can be regulated by sialylation
and desialylation. Inflammatory activation of microglia induces extracellular neuraminidases (NEU) that desialylates multiple targets. (a) Neuronal
desialylation promotes binding of galectin-3 (Gal-3), which stimulates microglial phagocytosis of neurons via c-mer proto-oncogene tyrosine
kinase (MerTK). Furthermore, microglial desialylation induces activation of complement receptor 3 (CR3) and toll-like receptor 4 (TLR4),
promoting phagocytosis of neurons and microglial activation. (b) Desialylation of dendrites increases binding of the “activated” complement
complex C1 (C10) to dendrites, which initiates the classical complement pathway with formation of the classical C3-convertase (dashed arrow),
that is leading to cleavage of C3 into C3a and C3b, as well as iC3b. The signaling fragment iC3b activates microglial phagocytosis via complement
receptor 3 (CR3). Removal of surface sialic acid also reduces binding of the regulatory complement factor H (FH), thus enhancing formation of
alternative C3-convertase (C3bBb), that is also leading to cleavage of C3 into C3a and C3b, as well as iC3b. C10 deposition at the synapse is
probably also mediated by desialylation. (c) Desialylation of neurons and microglia decreases cis and trans sialic acid binding immunoglobulin-like
lectin (SIGLEC) binding, thus reducing the homeostatic inhibitory signaling that normally counteracts the phagocytosis pathways in microglia
(a and b). Bb, fragment of cleaved complement factor B; C10, “activated” C1qC1r2C1s complex; C3b, fragment of cleaved complement component
3; CR3, complement receptor 3; FH, complement factor H; iC3b, soluble C3 signaling fragment; NEU, neuraminidase; MerTK, Mer Tyrosine
Kinase; Gal-3, galectin-3; TLR4, toll-like receptor 4; SIGLEC, sialic acid binding immunoglobulin-like lectin
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essential roles of Sias. Recently, we analyzed the effect of partial des-
ialylation by using viable heterozygous Gne knockout mice with a mild
(20–30%) reduction in sialylation (Klaus et al., 2020). We discovered
that microglia were activated at 6–9 months of age with reduced arbori-
zation and reduced synapse numbers in the heterozygous Gne knockout
mice. In parallel, a gradually increased neuronal loss in the brain was
found at 12 months of age that was not present in the wildtype control
mice. Interestingly, by crossbreeding these mice with complement C3-
deficient mice, we were able to restore the loss of neurons and synap-
ses, as well as the reduced microglial arborization, confirming the
complement C3-dependent removal of desialylated structures (Klaus
et al., 2020). Of note, synapse loss is also found in different neurodegen-
erative diseases, including AD and it was demonstrated that the knock-
out of complement proteins C1q, C3, or CR3 is able to prevent synaptic
and memory loss in animal models of these diseases (Schafer &
Stevens, 2010). In summary, these data suggest that the sialylation sta-
tus in the “Sia-complement” axis plays a critical role in modulating micro-
glial phagocytosis in both aging and neurodegenerative diseases.
In humans, mutations in the GNE gene lead to a group of genetic
disorders known as “GNE myopathy.” The main clinical features are pro-
gressive muscle atrophy and weakness leading to wheelchair-bound
patients, while the histopathology shows desialylation of specific muscle
proteins and “rimmed” vacuole inclusions in the affected muscle tissue.
Interestingly, abnormal accumulations of Aβ protein, ubiquitin, and phos-
phorylated tau protein, accompanied by cell stress, can be found in some
of the degenerating muscle fibers (Argov & Yarom, 1984; Murakami
et al., 1995; Muth et al., 2009; J. Schmidt et al., 2012), but no protein
aggregates have so far been described in the CNS of these patients. Sim-
ilar findings were seen in transgenic mouse models bearing the human
GNE D176V (Anada et al., 2014; Cho et al., 2017; Malicdan, Noguchi,
Nonaka, Hayashi, & Nishino, 2007) or the human GNE M712T mutation
(Galeano et al., 2007), but the mechanism leading to protein aggregation
in muscle tissue is not fully understood. However, it has been proposed
that the protein aggregation seen in GNE myopathy might share some
common pathogenic mechanisms with the accumulation of Aβ protein in
the AD brain.
In summary, sialylation of CNS cells appears to inhibit microglial
activation and phagocytosis by (a) blocking complement C3 activation
and opsonization, (b) blocking binding of the opsonin and alarmin
galectin-3, (c) inhibiting some key innate immune receptors such as
TLR4, and (d) activating inhibitory SIGLEC receptors. Thereby,
sialylation can be seen as a general “OFF” switch or immune check-
point, while desialylation removes this regulating checkpoint.
7 | CONCLUSIONS
Sias keep the CNS innate immune response in homeostasis by
inhibiting complement, as well as microglia via SIGLECs and other
receptors. Interestingly, the level of Sias is strictly regulated in the
CNS environment (cell type, subcellular structure and individual pro-
tein) and time (development, aging, and inflammation), allowing local
and conditional responses without changing the overall activation
profile of cells. Thus, the Sia checkpoint is a promising therapeutic tar-
get to treat human neuroinflammation and neurodegeneration. How-
ever, it is still unclear which disease types and at which disease stage
the inhibitory effects of Sias should be strengthened or weakened.
While some data indicate that a weakening of this axis for example
might help to clear Aβ plaques in AD animal models, the overall concept
suggests strengthening the inhibitory effect of Sias to avoid excessive
inflammatory, complement and radical-mediated damage of postmitotic
neuronal cells. In particular, desialylation triggers microglial activation,
oxidative damage, microglial phagocytosis of neurons and accumulation
of oxidized lipids and proteins. Likewise, failure of neuraminidases to
digest sialoconjugates also triggers accumulation of lipids and protein
aggregates. Thus, more data and a better understanding of the fine-
tuning of this crucial Sia checkpoint are urgently required.
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